1. Home
  2. JAZZ
  3. JAZZ News

Latest Jazz Pharmaceuticals plc (Ireland) (JAZZ) News on February 22, 2025

Jazz Pharmaceuticals to Participate in TD Cowen's 45th Annual Health Care Conference
JAZZ

PR Newswire

2 days ago

Jazz Pharmaceuticals to Participate in TD Cowen's 45th Annual Health Care Conference

Jazz (JAZZ) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
JAZZ

Zacks

2 days ago

Jazz (JAZZ) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

JAZZ

Argus Research

4 days ago

JAZZ: Raising target price to $149.00

Jazz (JAZZ) Surges 5.2%: Is This an Indication of Further Gains?
JAZZ

Zacks

10 days ago

Jazz (JAZZ) Surges 5.2%: Is This an Indication of Further Gains?

Jazz Pharmaceuticals to Report 2024 Full Year and Fourth Quarter Financial Results on February 25, 2025
JAZZ

PR Newswire

11 days ago

Jazz Pharmaceuticals to Report 2024 Full Year and Fourth Quarter Financial Results on February 25, 2025

Why Jazz (JAZZ) is Poised to Beat Earnings Estimates Again
JAZZ

Zacks

17 days ago

Why Jazz (JAZZ) is Poised to Beat Earnings Estimates Again

JAZZ

Argus Research

18 days ago

JAZZ: Lowering target price to $134.00

JAZZ

Argus Research

25 days ago

JAZZ: Raising target price to $136.00

JAZZ

Argus Research

a month ago

JAZZ: Lowering target price to $133.00

JP Morgan 2025: Jazz Pharmaceuticals focusing on oncology pipeline
JAZZ

Clinical Trials Arena

a month ago

JP Morgan 2025: Jazz Pharmaceuticals focusing on oncology pipeline

Jazz Pharmaceuticals plc (JAZZ): Analysts Recommend This 52-Week High Stocks Now
JAZZ

Insider Monkey

a month ago

Jazz Pharmaceuticals plc (JAZZ): Analysts Recommend This 52-Week High Stocks Now

JAZZ

Argus Research

a month ago

JAZZ: What does Argus have to say about JAZZ?

JAZZ

Argus Research

2 months ago

JAZZ: Raising target price to $137.00

JAZZ

Argus Research

2 months ago

JAZZ: Raising target price to $135.00

Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
JAZZ

PR Newswire

2 months ago

Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

JAZZ

MT Newswires

2 months ago

Jazz Pharmaceuticals CEO Bruce Cozadd Plans to Retire

Jazz Pharmaceuticals Announces CEO Succession Plan
JAZZ

PR Newswire

2 months ago

Jazz Pharmaceuticals Announces CEO Succession Plan

JAZZ

MT Newswires

2 months ago

Truist Securities Adjusts Jazz Pharmaceuticals Public Price Target to $220 From $200, Maintains Buy Rating

Is Now The Time To Put Jazz Pharmaceuticals (NASDAQ:JAZZ) On Your Watchlist?
JAZZ

Simply Wall St.

2 months ago

Is Now The Time To Put Jazz Pharmaceuticals (NASDAQ:JAZZ) On Your Watchlist?

Jazz upgraded to Overweight at Morgan Stanley after Ziihera launch
JAZZ

TipRanks

2 months ago

Jazz upgraded to Overweight at Morgan Stanley after Ziihera launch

5 High ROE Stocks to Buy as Volatility Weighs on Markets
JAZZ

Zacks

2 months ago

5 High ROE Stocks to Buy as Volatility Weighs on Markets

JAZZ

Argus Research

2 months ago

JAZZ: Lowering target price to $132.00

JAZZ

MT Newswires

2 months ago

Jazz Pharmaceuticals Likely to Launch FDA-Approved Biliary Tract Cancer Treatment in 2025, RBC Says

Jazz Pharmaceuticals to Showcase New Real-World Evidence Reinforcing Epidiolex® (cannabidiol) Benefits and Broad-Spectrum Efficacy in Treatment-Resistant Epilepsies at the American Epilepsy Society 2024 Annual Meeting
JAZZ

PR Newswire

3 months ago

Jazz Pharmaceuticals to Showcase New Real-World Evidence Reinforcing Epidiolex® (cannabidiol) Benefits and Broad-Spectrum Efficacy in Treatment-Resistant Epilepsies at the American Epilepsy Society 2024 Annual Meeting

Jazz (JAZZ) Up 3.4% Since Last Earnings Report: Can It Continue?
JAZZ

Zacks

3 months ago

Jazz (JAZZ) Up 3.4% Since Last Earnings Report: Can It Continue?

Jazz Pharmaceuticals Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Biliary Tract Cancers to Include zanidatamab-hrii (Ziihera®)
JAZZ

PR Newswire

3 months ago

Jazz Pharmaceuticals Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Biliary Tract Cancers to Include zanidatamab-hrii (Ziihera®)

Jazz Pharmaceuticals Announces Ziihera® (zanidatamab-hrii) Investor Webcast on December 11, 2024
JAZZ

PR Newswire

3 months ago

Jazz Pharmaceuticals Announces Ziihera® (zanidatamab-hrii) Investor Webcast on December 11, 2024

JAZZ

Argus Research

3 months ago

JAZZ: Lowering target price to $134.00

Jazz Pharmaceuticals to Present Advancements in Solid Tumors and Blood Cancer Research at San Antonio Breast Cancer Symposium and American Society of Hematology Annual Meeting
JAZZ

PR Newswire

3 months ago

Jazz Pharmaceuticals to Present Advancements in Solid Tumors and Blood Cancer Research at San Antonio Breast Cancer Symposium and American Society of Hematology Annual Meeting

Wall Street Analysts Think Jazz (JAZZ) Could Surge 44.37%: Read This Before Placing a Bet
JAZZ

Zacks

3 months ago

Wall Street Analysts Think Jazz (JAZZ) Could Surge 44.37%: Read This Before Placing a Bet

Why Jazz Pharmaceuticals (JAZZ) Is One of the Most Undervalued Pot Stocks to Buy?
JAZZ

Insider Monkey

3 months ago

Why Jazz Pharmaceuticals (JAZZ) Is One of the Most Undervalued Pot Stocks to Buy?

JAZZ

Argus Research

3 months ago

JAZZ: Rating increased to a BUY

ChromaDex Corporation (CDXC) Hits Fresh High: Is There Still Room to Run?
JAZZ

Zacks

3 months ago

ChromaDex Corporation (CDXC) Hits Fresh High: Is There Still Room to Run?

Jazz Pharmaceuticals price target lowered to $163 from $166 at Piper Sandler
JAZZ

TipRanks

3 months ago

Jazz Pharmaceuticals price target lowered to $163 from $166 at Piper Sandler

JAZZ

MT Newswires

3 months ago

Sector Update: Health Care Stocks Rise Pre-Bell Thursday

JAZZ

MT Newswires

3 months ago

Sector Update: Health Care

JAZZ

MT Newswires

3 months ago

Zymeworks, Jazz Pharmaceuticals Receive FDA's Accelerated Approval for Ziihera to Treat Biliary Tract Cancer

JAZZ

MT Newswires

3 months ago

Jazz Pharmaceuticals Receives US FDA Accelerated Approval for Biliary Tract Cancer Treatment

Jazz Pharmaceuticals Announces U.S. FDA Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)
JAZZ

PR Newswire

3 months ago

Jazz Pharmaceuticals Announces U.S. FDA Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)

Jazz Pharmaceuticals to Participate in Citi's 2024 Global Healthcare Conference
JAZZ

PR Newswire

3 months ago

Jazz Pharmaceuticals to Participate in Citi's 2024 Global Healthcare Conference

JAZZ

MT Newswires

3 months ago

UBS Raises Price Target on Jazz Pharmaceuticals Public to $128 From $121, Maintains Neutral Rating

Should Value Investors Buy Jazz Pharmaceuticals (JAZZ) Stock?
JAZZ

Zacks

3 months ago

Should Value Investors Buy Jazz Pharmaceuticals (JAZZ) Stock?

Silver Ring Value Partners: Jazz Pharmaceuticals (JAZZ) Is a “High Uncertainty With Low Risk” Investment
JAZZ

Insider Monkey

3 months ago

Silver Ring Value Partners: Jazz Pharmaceuticals (JAZZ) Is a “High Uncertainty With Low Risk” Investment

Is Jazz Pharmaceuticals plc (JAZZ) the Best Immunotherapy Stock to Buy Now?
JAZZ

Insider Monkey

3 months ago

Is Jazz Pharmaceuticals plc (JAZZ) the Best Immunotherapy Stock to Buy Now?

Is the Options Market Predicting a Spike in Jazz (JAZZ) Stock?
JAZZ

Zacks

3 months ago

Is the Options Market Predicting a Spike in Jazz (JAZZ) Stock?

Jazz Pharmaceuticals' (NASDAQ:JAZZ) Performance Is Even Better Than Its Earnings Suggest
JAZZ

Simply Wall St.

3 months ago

Jazz Pharmaceuticals' (NASDAQ:JAZZ) Performance Is Even Better Than Its Earnings Suggest

JAZZ

MT Newswires

3 months ago

Jazz Pharmaceuticals Insider Sold Shares Worth $456,617, According to a Recent SEC Filing

Jazz (JAZZ) Upgraded to Buy: Here's Why
JAZZ

Zacks

3 months ago

Jazz (JAZZ) Upgraded to Buy: Here's Why

JAZZ or CTLT: Which Is the Better Value Stock Right Now?
JAZZ

Zacks

3 months ago

JAZZ or CTLT: Which Is the Better Value Stock Right Now?

Wall Street Analysts See a 37.65% Upside in Jazz (JAZZ): Can the Stock Really Move This High?
JAZZ

Zacks

3 months ago

Wall Street Analysts See a 37.65% Upside in Jazz (JAZZ): Can the Stock Really Move This High?

Is Collegium Pharmaceutical (COLL) a Great Value Stock Right Now?
JAZZ

Zacks

3 months ago

Is Collegium Pharmaceutical (COLL) a Great Value Stock Right Now?

JAZZ

Argus Research

3 months ago

JAZZ: Raising target price to $134.00

Jazz Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations
JAZZ

Simply Wall St.

3 months ago

Jazz Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations

JAZZ

Morningstar Research

3 months ago

Analyst Report: Jazz Pharmaceuticals plc

Jazz (JAZZ) Reliance on International Sales: What Investors Need to Know
JAZZ

Zacks

3 months ago

Jazz (JAZZ) Reliance on International Sales: What Investors Need to Know

Tezspire succeeds in chronic rhinosinusitis; Gilead writes down Trodelvy value
JAZZ

BioPharma Dive

3 months ago

Tezspire succeeds in chronic rhinosinusitis; Gilead writes down Trodelvy value

JAZZ

Morningstar Research

3 months ago

Analyst Report: Jazz Pharmaceuticals plc

Jazz Pharmaceuticals PLC (JAZZ) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...
JAZZ

GuruFocus.com

3 months ago

Jazz Pharmaceuticals PLC (JAZZ) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...

Compared to Estimates, Jazz (JAZZ) Q3 Earnings: A Look at Key Metrics
JAZZ

Zacks

4 months ago

Compared to Estimates, Jazz (JAZZ) Q3 Earnings: A Look at Key Metrics

Jazz Pharmaceuticals (JAZZ) Q3 Earnings and Revenues Top Estimates
JAZZ

Zacks

4 months ago

Jazz Pharmaceuticals (JAZZ) Q3 Earnings and Revenues Top Estimates

JAZZ

Associated Press Finance

4 months ago

Jazz: Q3 Earnings Snapshot

Jazz Pharmaceuticals Announces Third Quarter 2024 Financial Results
JAZZ

PR Newswire

4 months ago

Jazz Pharmaceuticals Announces Third Quarter 2024 Financial Results

JAZZ

Argus Research

4 months ago

JAZZ: Rating decreased to a HOLD

Insights Into Jazz (JAZZ) Q3: Wall Street Projections for Key Metrics
JAZZ

Zacks

4 months ago

Insights Into Jazz (JAZZ) Q3: Wall Street Projections for Key Metrics

Jazz Pharmaceuticals Presents New Data at Psych Congress 2024 Confirming Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Benefits in Narcolepsy and Idiopathic Hypersomnia
JAZZ

PR Newswire

4 months ago

Jazz Pharmaceuticals Presents New Data at Psych Congress 2024 Confirming Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Benefits in Narcolepsy and Idiopathic Hypersomnia

Esperion Therapeutics (ESPR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
JAZZ

Zacks

4 months ago

Esperion Therapeutics (ESPR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Jazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: Should You Buy?
JAZZ

Zacks

4 months ago

Jazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: Should You Buy?

With A 10% Return On Equity, Is Jazz Pharmaceuticals plc (NASDAQ:JAZZ) A Quality Stock?
JAZZ

Simply Wall St.

4 months ago

With A 10% Return On Equity, Is Jazz Pharmaceuticals plc (NASDAQ:JAZZ) A Quality Stock?

Jazz Pharmaceuticals plc (JAZZ): Among the Best Stocks to Buy for High Returns in 2024
JAZZ

Insider Monkey

4 months ago

Jazz Pharmaceuticals plc (JAZZ): Among the Best Stocks to Buy for High Returns in 2024

Jazz Pharmaceuticals price target raised to $179 from $175 at RBC Capital
JAZZ

TipRanks

4 months ago

Jazz Pharmaceuticals price target raised to $179 from $175 at RBC Capital

Jazz Pharmaceuticals to Report 2024 Third Quarter Financial Results on November 6, 2024
JAZZ

PR Newswire

4 months ago

Jazz Pharmaceuticals to Report 2024 Third Quarter Financial Results on November 6, 2024

JAZZ

MT Newswires

4 months ago

RBC Raises Price Target on Jazz Pharmaceuticals to $179 From $175, Keeps Outperform Rating

Avadel wins FDA approval for narcolepsy drug Lumryz in children
JAZZ

Pharmaceutical Technology

4 months ago

Avadel wins FDA approval for narcolepsy drug Lumryz in children

Billionaire Seth Klarman Sold 64% of Baupost's Stake in Alphabet and Is Piling Into This Historically Cheap and Under-the-Radar Drugmaker
JAZZ

Motley Fool

4 months ago

Billionaire Seth Klarman Sold 64% of Baupost's Stake in Alphabet and Is Piling Into This Historically Cheap and Under-the-Radar Drugmaker

Wall Street Analysts Think Jazz (JAZZ) Could Surge 51.8%: Read This Before Placing a Bet
JAZZ

Zacks

4 months ago

Wall Street Analysts Think Jazz (JAZZ) Could Surge 51.8%: Read This Before Placing a Bet

Are Investors Undervaluing Jazz Pharmaceuticals (JAZZ) Right Now?
JAZZ

Zacks

4 months ago

Are Investors Undervaluing Jazz Pharmaceuticals (JAZZ) Right Now?

Is Jazz Pharmaceuticals plc (JAZZ) the Most Promising Biotech Stock According to Hedge Funds?
JAZZ

Insider Monkey

4 months ago

Is Jazz Pharmaceuticals plc (JAZZ) the Most Promising Biotech Stock According to Hedge Funds?

JAZZ vs. ZTS: Which Stock Is the Better Value Option?
JAZZ

Zacks

4 months ago

JAZZ vs. ZTS: Which Stock Is the Better Value Option?

JAZZ Stock Soars After Combo Therapy Meets Goal in Lung Cancer Study
JAZZ

Zacks

4 months ago

JAZZ Stock Soars After Combo Therapy Meets Goal in Lung Cancer Study

Is Jazz Pharmaceuticals (JAZZ) the Best Small-Cap Value Stock to Buy According to Hedge Funds?
JAZZ

Insider Monkey

4 months ago

Is Jazz Pharmaceuticals (JAZZ) the Best Small-Cap Value Stock to Buy According to Hedge Funds?

Jazz Pharmaceuticals’ Zepzelca combination meets endpoints in lung cancer trial
JAZZ

TipRanks

4 months ago

Jazz Pharmaceuticals’ Zepzelca combination meets endpoints in lung cancer trial

Jazz Pharmaceuticals' Zepzelca/Tecentriq Combo Regimen Can Potentially Delay Disease Progression, Extend Survival In Aggressive Form Of Lung Cancer
JAZZ

Benzinga

4 months ago

Jazz Pharmaceuticals' Zepzelca/Tecentriq Combo Regimen Can Potentially Delay Disease Progression, Extend Survival In Aggressive Form Of Lung Cancer

PharmaMar Announces Positive and Statistically Significant Overall Survival and Progression-Free Survival Results for Zepzelca® (lurbinectedin) and Atezolizumab Combination in First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
JAZZ

PR Newswire

4 months ago

PharmaMar Announces Positive and Statistically Significant Overall Survival and Progression-Free Survival Results for Zepzelca® (lurbinectedin) and Atezolizumab Combination in First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

JAZZ

MT Newswires

4 months ago

Jazz Pharmaceuticals Reports Positive Preliminary Results in Clinical Trial of Potential Lung Cancer Treatment

Jazz Pharmaceuticals Announces Statistically Significant Overall Survival and Progression-Free Survival Results for Zepzelca® (lurbinectedin) and Atezolizumab Combination in First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
JAZZ

PR Newswire

4 months ago

Jazz Pharmaceuticals Announces Statistically Significant Overall Survival and Progression-Free Survival Results for Zepzelca® (lurbinectedin) and Atezolizumab Combination in First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Pfizer invests in molecular glue; Jazz, MeiraGTx shares rise on drug data
JAZZ

BioPharma Dive

4 months ago

Pfizer invests in molecular glue; Jazz, MeiraGTx shares rise on drug data

Wall Street Analysts Favor Jazz Pharmaceuticals plc (JAZZ) for Biopharma Growth
JAZZ

Insider Monkey

4 months ago

Wall Street Analysts Favor Jazz Pharmaceuticals plc (JAZZ) for Biopharma Growth

Is Jazz Pharmaceuticals plc (NASDAQ:JAZZ) The Top Stock With Improving Technical Ratings According To Piper Sandler?
JAZZ

Insider Monkey

4 months ago

Is Jazz Pharmaceuticals plc (NASDAQ:JAZZ) The Top Stock With Improving Technical Ratings According To Piper Sandler?

Will Auvelity & Sunosi Fuel Axsome's Growth Amid Stiff Competition?
JAZZ

Zacks

4 months ago

Will Auvelity & Sunosi Fuel Axsome's Growth Amid Stiff Competition?

Jazz Pharmaceuticals plc (JAZZ): Among The Stocks With Biggest Upside Potential According to Hedge Funds
JAZZ

Insider Monkey

4 months ago

Jazz Pharmaceuticals plc (JAZZ): Among The Stocks With Biggest Upside Potential According to Hedge Funds

JAZZ

Argus Research

4 months ago

JAZZ: Lowering target price to $118.00

Jazz Pharmaceuticals Plc (JAZZ): Among Seth Klarman’s Top Stock Picks
JAZZ

Insider Monkey

4 months ago

Jazz Pharmaceuticals Plc (JAZZ): Among Seth Klarman’s Top Stock Picks

Jazz Pharmaceuticals: Unveiling Growth Potential From Non-Small Cell Lung Cancer Market
JAZZ

GuruFocus.com

5 months ago

Jazz Pharmaceuticals: Unveiling Growth Potential From Non-Small Cell Lung Cancer Market

JAZZ

MT Newswires

5 months ago

RBC Lifts Price Target on Jazz Pharmaceuticals to $175 From $174, Keeps Outperform Rating

Jazz Pharmaceuticals plc (JAZZ): Why Are Hedge Funds Bullish On This Cheap Growth Stock Right Now?
JAZZ

Insider Monkey

5 months ago

Jazz Pharmaceuticals plc (JAZZ): Why Are Hedge Funds Bullish On This Cheap Growth Stock Right Now?

Here's Why You Should Consider Buying Jazz Pharmaceuticals' Stock
JAZZ

Zacks

5 months ago

Here's Why You Should Consider Buying Jazz Pharmaceuticals' Stock

Is Jazz Pharmaceuticals (JAZZ) Stock Undervalued Right Now?
JAZZ

Zacks

5 months ago

Is Jazz Pharmaceuticals (JAZZ) Stock Undervalued Right Now?

Jazz Pharmaceuticals' (NASDAQ:JAZZ) earnings have declined over five years, contributing to shareholders 16% loss
JAZZ

Simply Wall St.

5 months ago

Jazz Pharmaceuticals' (NASDAQ:JAZZ) earnings have declined over five years, contributing to shareholders 16% loss

JAZZ

MT Newswires

5 months ago

Jazz Pharmaceuticals Says Gastric Cancer Therapy Shows Promise in Mid-Stage Study

Jazz Pharmaceuticals Presents Updated Phase 2 Data for Zanidatamab Demonstrating Increased mPFS in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ESMO 2024
JAZZ

PR Newswire

5 months ago

Jazz Pharmaceuticals Presents Updated Phase 2 Data for Zanidatamab Demonstrating Increased mPFS in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ESMO 2024

Share on Social Networks: